GUMDROP : JHMI J1287 A Randomized, Open-Label, Phase 3 Study of BMS-936558 vs. Everolimus in Subjects With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy

Created by Nancy Dawson, last modified on Sep 16, 2013
Description:The purpose of the study is to compare the clinical benefit, as measured by duration of overall survival, of BMS-936558 vs. Everolimus in subjects with advanced or metastatic clear-cell renal cell carcinoma who have received prior anti-angiogenic therapy
Link:http://clinicaltrials.gov/ct2/show/NCT01668784
Site:Johns Hopkins Hospital
Principle Investigator:Jenny Kim